Arthrosis

Micronutrient therapy

Summary

Osteoarthritis is a chronic, non-inflammatory, age-related, degenerative disease of the musculoskeletal system and belongs to the rheumatic system.(1)(2) The clinical picture of osteoarthritis is mainly characterized by joint pain and loss of function in the later stages of the disease, even during periods of immobility, but is initially asymptomatic due to pain during movement or prolonged loading of the affected joint. (3)(4)(5) Risk factors for the development of osteoarthritis include age, female gender, familial predisposition, obesity, muscle weakness, joint injury, and joint overload due to deformity or unilateral loading and immobilization. (6) Although any joint can be affected by osteoarthritis, hip and knee osteoarthritis are among the most commonly diagnosed.(7) In terms of therapy, both pharmacologic and nonpharmacologic treatment options are available, with medications being used when lifestyle modifications and physical measures do not achieve the desired goal. (8)(9) As a last resort, joint fusion or an artificial joint may be considered.(10) Worldwide, osteoarthritis affects millions of people, predominantly women, and the incidence increases with age.(11) The prognosis of the disease in patients depends on which and how many joints are affected, the extent of symptoms, and the degree of functional impairment(s).
 

Causes

The cause of osteoarthritis is attributed to an interaction of several factors, including risk factors such as age, female gender, obesity, anatomical factors, muscle weakness, lack of exercise and joint injuries (occupation, sports), as well as overloading and misalignment of the joints. (7) Due to this, there is a disturbed balance of the degrading and regenerating processes of the cartilage, which results in a decrease in the thickness of the cartilage tissue.(13) Basically, it can be observed that the first arthritic changes are irregularities and erosions on the articular cartilage. The erosions continue to expand and extend to the bone.(14)(15) After cartilage injury, damage to the collagen matrix, proliferation of chondrocytes and clustering can be seen under the microscope. The chondrocytes become hypertrophic and cause cartilage outgrowths that form osteophytes and ossify.(16) Depending on the damage to the collagen matrix, more or fewer chondrocytes become apoptotic.(16)(17) Insufficiently mineralized collagen causes thickening of the subchondral bone (subchondral sclerosis); bone cysts sometimes occur in advanced disease. To some extent, there is also inflammation and hypertrophy of the synovial membranes, although unlike inflammatory arthritis, this is not the precipitating factor.(18).
 

Symptoms

The course and appearance of osteoarthritis vary from person to person. However, the disease manifests itself in most people through joint pain and restricted movement; but the joint spaces themselves can also be sensitive.(20) Joint pain is mostly dependent on the stage of the disease and whether activated osteoarthritis is present. Whereas pain in the early stages of osteoarthritis depends on physical activity - including pain on onset, exertion, and fatigue - and resolves with immobility, prolonged pain occurs as osteoarthritis progresses, such as pain at rest, at night, and persistent pain. At first, these only interfere with daily activities, but can then lead to severe limitations in function and severely affect the patient's quality of life. (21)(22) From a medical point of view, osteoarthritis usually affects either the upper or lower extremities, and there it mainly affects the distal interphalangeal joints (Heberden's arthrosis with Heberden's nodes), the proximal interphalangeal (PIP) joints (Bouchard's arthrosis with Bouchard's nodes at the finger middle joints), the carpometacarpal joint (rhizarthrosis or thumb saddle joint arthritis with swelling of the base of the thumb and predominant pain on grasping and turning), the hip (coxarthrosis or hip joint arthritis), the knees (gonarthrosis or knee joint arthritis), the metatarsophalangeal joints (hallux ridigus or Osteoarthritis of the metatarsophalangeal joint (hallux ridigus or arthritis of the metatarsophalangeal joint), the shoulder (omarthrosis or arthritis of the shoulder joint), and the joints of the lower cervical and lumbar spine.(23)(24)(25)(26)(27)(28)(29) In addition, osteoarthritis may be monoarticular (affecting one joint) or polyarticular (affecting several joints).(30)
 

Diagnostics

In addition to anamnesis, the diagnosis of osteoarthritis usually consists of imaging procedures and, if necessary, a blood test to exclude diseases with similar symptoms, such as rheumatoid arthritis, on the basis of various blood parameters, including rheumatoid factor, erythrocyte sedimentation rate, and antinuclear antibodies. Osteoarthritis is suspected when the patient is over 45 years of age, complains of pain that worsens with activity and improves at rest, bony joint enlargement is noted, and range of motion is limited. (31)(32) Radiography may reveal findings suggestive of osteoarthritis, including uneven joint space narrowing due to decrease in cartilage thickness, marginal osteophytes, compaction of bone tissue in the form of subchondral sclerosis, and subchondral cysts. (33) Sonography is another way to identify osteophytes and inflammation of the synovial membrane that may be associated with osteoarthritis.(34) There are several classification systems for osteoarthritis that incorporate stage and radiographic appearance, including the Kellgren-Lawrence classification and the American College of Rheumatolgy classification.(35)(36)
 

Therapy 

The treatment of osteoarthritis is primarily aimed at relieving pain and restoring the function of the joint or minimizing its limitation. Non-pharmacological and pharmacological therapies are used for osteoarthritis. For patients with mild symptoms, nonpharmacologic therapy is the first choice; for patients with an advanced form, a combination of both is required.(9)(10) The most important nonpharmacologic therapies include avoidance of activities that exacerbate pain or lead to joint overload, dosed targeted muscle-strengthening exercise, and weight loss for overweight and obesity. (37) The latter is essential, as each kilogram of body weight increases the load on the joint many times over.(38) Physical therapy can assist the patient with targeted exercises, and aerobic exercise and strength training have also been shown in studies to help reduce pain and improve physical function.(39)(40) Joint deformities should be corrected with mechanical means such as orthoses and knee braces. On the pharmacological level, peripherally acting analgesics such as acetaminophen as well as nonsteroidal anti-inflammatory drugs (NSAIDs) represent the most popular agents of choice, but opioid analgesics are also used. In addition, glucocorticoids may be injected intra-articularly in severe cases of osteoarthritis.(9)(41) If neither non-pharmacological nor pharmacological therapy is effective, joint replacement (endoprosthesis) or surgical joint fusion (arthrodesis) may be a last resort.(42)
 

Relevant micronutrients
Promote formation of synovial fluid

Glucosamine sulfate, chondroitin sulfate and hyaluronic acid are the classics in the nutritive accompanying arthrosis therapy. As natural joint building blocks, they help to form the synovial fluid. Through their water-binding capacity, the substances ensure the elasticity and suppleness of the cartilage, the optimal viscosity of the synovial fluid and thus a better buffer function, which reduces pain. In addition, the substances contained in the synovium serve as a substrate for the chondrocytes, which must be regularly regenerated.

Native type II collagen is an essential component of cartilage tissue. Only native type II collagen possesses the special triple helix necessary for tear-resistant collagen fibers. As a catalyst, native type II collagen also stabilizes tendons and connective tissue. Vitamin C also plays a significant role in the maintenance of collagen.

Calcium and vitamin D are key micronutrients in bone metabolism and thus important for stabilizing joints. Manganese is a coenzyme of glycosyltransferase. This is involved in the biosynthesis of proteoglycans of cartilage and connective tissue. Furthermore, as an antioxidant component, manganese can positively influence the inflammatory process via superoxide dismutase.
 

Supply antioxidants
Patients with osteoarthritis exhibit increased oxidative stress systemically and locally. Reactive oxygen species (ROS), which are generated as a result of abnormal chondrocyte metabolism, lead to increased oxidative stress. The increased occurrence of ROS can accelerate the destruction of tissue structures and promote inflammation. The supply of antioxidants as well as integral trace elements (copper, manganese, selenium) and antioxidant enzymes can reduce further oxidative damage as well as have a positive effect on the inflammatory process.

 

Reduce inflammation and pain 

Frankincense extract (Boswellia serrata) contains boswellic acids, triterpenic acids as well as terpene alcohols and is particularly suitable for the treatment of acute and chronic pain caused by inflammatory processes in joints, muscles and the spine. 

Proteolytic enzymes represent an efficient therapeutic agent for acute and chronic inflammations. Proteases accelerate the course of the inflammatory process by disposing of necrotic tissue remnants and have an analgesic effect due to their anti-edemic properties. Especially in acute therapy, the anti-edematous and fibrinolytic effects are considered scientifically proven. Post-traumatic swelling after surgical interventions can also be reduced significantly faster by enzyme administration, which also noticeably reduces pain. 

In studies, S-adenosylmethionine (SAM) has shown promising analgesic and antiphlogistic effects in osteoarthritis with an analgesic effect comparable to that of NSAIDs. Methylsulfonylmethane (MSM) is suitable for therapeutic use especially for pain associated with osteoarthritis, arthritis or sports injuries. The mechanism of action is thought to be the inhibition of cyclooxygenase. In addition, MSM is said to shorten the regeneration time of overtrained muscle parts and allow injuries to heal more quickly. 

Diagnostic tests

Available laboratory tests (Laboratory GANZIMMUN) Detailed information
Cartilage Oligomeric Matrix Protein Laboratory parameters for articular cartilage destruction in inflammatory and degenerative joint diseases COMP

 

References

References

1. Loeser, R. F. et al. 2012. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 64(6):1697-707.
2. Junge-Hülsing, G. 1975. Rheumatischer Formenkreis. Geriatrie in der Praxis. 100-116.  
3. Bortoluzzi, A., Furini, F., Scirè, C. A. 2018. Osteoarthritis and its management - Epidemiology, nutritional aspects and environmental actors. Autoimmun Rev. 17(11):1097-1104. 
4. Miller, A. et al. 2017. Radiographic Patterns of Radiocarpal and Midcarpal Arthritis. J Am Acad Orthop Surg Glob Res Rev. 1(3):e017. 
5. Berenbaum, F. et al. 2018. Modern-day environmental factors in the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 14(11):674-681. 
6. Palazzo, C. et al. 2016. Risk factors and burden of osteoarthritis. Ann Phys Rehabil Med. 59(3):134-138.
7. Theiler, R. 2002. Arthrose. Epidemiologie, Diagnose und Differentialdiagnose, Abklärung und Dokumentation. Schweiz Med Forum Nr. 23.
8. Steinmeyer, J. et al. 2018. Pharmacological treatment of knee osteoarthritis: Special considerations of the new German guideline. Orthop Rev (Pavia). 10(4): 7782.
9. Ferreira, R. M. et al. 2019. Non-Pharmacological and Non-Surgical Interventions for Knee Osteoarthritis: A Systematic Review and Meta-Analysis. Acta Rheumatol Port. 44(3):173-217.
10. Anandacoomarasamy, A. 2010. Current Evidence for Osteoarthritis Treatments. Ther Adv Musculoskelet Dis. 2(1): 17–28.
11. Anderson, A. S., Loeser, R. F. 2010. Why is Osteoarthritis an Age-Related Disease? Best Pract Res Clin Rheumatol. 24(1): 15.
12. Mahajan, A., Verma, S., Tandon, V. 2005. Osteoarthritis. J Assoc Physicians India. 53:634-41.
13. Mahajan, A., Verma, S., Tandon, V. 2005. Osteoarthritis. J Assoc Physicians India. 53:634-41.
14. Mobasheri, A., Batt, M. 2016. An update on the pathophysiology of osteoarthritis. Ann Phys Rehabil Med. 59(5-6):333-339.
15. Sinusas, K. 2012. Osteoarthritis: diagnosis and treatment. Am Fam Physician. 85(1):49-56.
16. Aigner, T., et al. 2007. Mechanisms of disease: role of chondrocytes in the pathogenesis of osteoarthritis--structure, chaos and senescence. Nat Clin Pract Rheumatol. 3(7):391-9.
17. Goldring, M. B. 2000. The role of the chondrocyte in osteoarthritis. Arthritis & Rheumatism. 43: 1916-1926.
18. Goldring, M. B., Goldring, S. R. 2010. Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis. Skeletal Biololgy and Medicine. 1192(1): 230-237.
20. Zacher, J., Gursche, A. 2001. Diagnostik der Arthrose. Der Orthopäde. 30: 841-847.
21. O’Neill, T. W., Felson, D. T. 2018. Mechanism of Osteoarthritis (OA) Pain. Curr Osteoporos Rep. 16(5): 611–616.
22. Neogi, T. 2013. The epidemiology and impact of pain in osteoarthritis. Osteoarthritis Cartilage. 21(9):1145-53.
23. Stecher, R. M., 1955. Heberden's nodes; a clinical description of osteo-arthritis of the finger joints. Ann Rheum Dis. 14(1):1-10.
24. Alexander, C. 1999. Heberden’s and Bouchard’s nodes. Ann Rheum Dis. 58(11): 675–678.
25. Van Schoonhoven, J. Rhizarthrose. 2021. Operative Orthopädie und Traumatologie. 33: 181-182.
26. Imhof, H. et al. 2002. Coxarthrosis. Radiologie. 42(6):416-31.
27. Kwiatkowski, K., Plominski, J. 2004. Gonarthrosis – pathomechanism and diagnosis. Pol Merkur Lekarski. 17(100):415-9.
28. Ho, B., Baumhauer, J. 2017. Hallux ridigus. EFFORT Open Rev. 2(1): 13–20.
29. Wülker, N. 2000. Omarthrosis. Orthopade. 29(10):909-16.
30. Sen, R., Hurley J. A. 2022. Osteoarthritis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.
31. Chinese Orthopaedic Association. 2010. Diagnosis and treatment of osteoarthritis. Orthop Surg. 2(1): 1–6.
32. Ackerman, I. N. 2017. The feasibility of implementing the ICHOM Standard Set for Hip and Knee Osteoarthritis: a mixed-methods evaluation in public and private hospital settings. J Patient Rep Outcomes. 2:32. 
33. Kijowski, R., et al. 2006. Radiographic findings of osteoarthritis versus arthroscopic findings of articular cartilage degeneration in the tibiofemoral joint. Radiology. 239(3):818-24.
34. Iagnocco, A., Palombi, G., Valesini, G. 2001. Role of ultrasound in osteoarthritis. 28;7:301-306.
35. Kohn, M. D. Sassoon, A. A., Fernando, N. D. 2016. Classifications in Brief: Kellgren-Lawrence Classification of Osteoarthrits. Clin Orthop Relat Res. 474(8): 1886–1893.
36. Kolasinski, S. et al. 2020. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 72(2):149-162.
37. Brosseau, L. et al. 2014. A Systematic Critical Appraisal for Non-Pharmacological Management of Osteoarthritis Using the Appraisal of Guidelines Research and Evaluation II Instrument. PLoS One. 9(1): e82986.
38. Bliddal, H., Leeds, A. R., Christensen, R. Osteoarthritis, obesity and weight loss: evidence, hypotheses and horizons - a scoping review. Obes Rev. 15(7):578-86.
39. Brakke, R., Singh, J., Sullivan, W. 2012. Physical therapy in persons with osteoarthritis. PM R. 4(5 Suppl):S53-8.
40. Semanik, P. et al. 2014. Aerobic Activity in Prevention & Symptom Control of Osteoarthritis. PM R4(5 0): S37–S44.
41. Cai, X. et al. 2021. New Trends in Pharmacological Treatments for Osteoarthritis. Front. Pharmacol. 12:645842.
42. Katz, J. N., Earp, B. E., Gomoll, A. H. 2010. Surgical Management of Osteoarthritis. Arthritis Care Res (Hoboken). 62(9): 1220–1228.

up